Exploratory Research Laboratory, Institute for Cancer Research and Treatment (IRCC), University of Turin Medical School, 10060 Candiolo, Turin, Italy.
Cancer Res. 2011 Mar 1;71(5):1945-55. doi: 10.1158/0008-5472.CAN-10-2100. Epub 2011 Jan 6.
Receptors for the scatter factors HGF and MSP that are encoded by the MET and RON oncogenes are key players in invasive growth. Receptor cross-talk between Met and Ron occurs. Amplification of the MET oncogene results in kinase activation, deregulated expression of an invasive growth phenotype, and addiction to MET oncogene signaling (i.e., dependency on sustained Met signaling for survival and proliferation). Here we show that cancer cells addicted to MET also display constitutive activation of the Ron kinase. In human cancer cell lines coexpressing the 2 oncogenes, Ron is specifically transphosphorylated by activated Met. In contrast, Ron phosphorylation is not triggered in cells harboring constitutively active kinase receptors other than Met, including Egfr or Her2. Furthermore, Ron phosphorylation is suppressed by Met-specific kinase inhibitors (PHA-665752 or JNJ-38877605). Last, Ron phosphorylation is quenched by reducing cell surface expression of Met proteins by antibody-induced shedding. In MET-addicted cancer cells, short hairpin RNA-mediated silencing of RON expression resulted in decreased proliferation and clonogenic activity in vitro and tumorigenicity in vivo. Our findings establish that oncogene addiction to MET involves Ron transactivation, pointing to Ron kinase as a target for combinatorial cancer therapy.
MET 和 RON 癌基因编码的散射因子 HGF 和 MSP 的受体是浸润性生长的关键因素。Met 和 Ron 受体间的交叉对话发生。MET 癌基因的扩增导致激酶激活、侵袭性生长表型的失调表达以及对 MET 癌基因信号的依赖(即,对持续的 Met 信号存活和增殖的依赖性)。在这里,我们表明,依赖 MET 的癌细胞也表现出 Ron 激酶的组成性激活。在共表达这 2 种癌基因的人类癌细胞系中,Ron 被激活的 Met 特异性地转磷酸化。相比之下,在除 Met 以外的其他组成性激活激酶受体(包括 Egfr 或 Her2)存在的细胞中,不会触发 Ron 磷酸化。此外,Ron 磷酸化被 Met 特异性激酶抑制剂(PHA-665752 或 JNJ-38877605)抑制。最后,通过抗体诱导的脱落减少细胞表面 Met 蛋白的表达,Ron 磷酸化被抑制。在 MET 依赖的癌细胞中,RON 表达的短发夹 RNA 介导的沉默导致体外增殖和集落形成活性降低以及体内致瘤性降低。我们的发现确立了对 MET 的致癌基因依赖性涉及 Ron 的转激活,表明 Ron 激酶是联合癌症治疗的一个靶点。